These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 8786955)

  • 1. Population pharmacokinetic modeling: the importance of informative graphics.
    Ette EI; Ludden TM
    Pharm Res; 1995 Dec; 12(12):1845-55. PubMed ID: 8786955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stability and performance of a population pharmacokinetic model.
    Ette EI
    J Clin Pharmacol; 1997 Jun; 37(6):486-95. PubMed ID: 9208355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus.
    Staatz CE; Tett SE
    Eur J Clin Pharmacol; 2002 Dec; 58(9):597-605. PubMed ID: 12483452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefepime in intensive care unit patients: validation of a population pharmacokinetic approach and influence of covariables.
    Georges B; Conil JM; Seguin T; Dieye E; Cougot P; Decun JF; Lavit M; Samii K; Houin G; Saivin S
    Int J Clin Pharmacol Ther; 2008 Apr; 46(4):157-64. PubMed ID: 18397688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: application to pefloxacin in intensive care unit patients.
    Bruno R; Iliadis MC; Lacarelle B; Cosson V; Mandema JW; Le Roux Y; Montay G; Durand A; Ballereau M; Alasia M
    J Pharmacokinet Biopharm; 1992 Dec; 20(6):653-69. PubMed ID: 1302767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of cefepime in neonates with severe nosocomial infections.
    Lima-Rogel V; Medina-Rojas EL; Del Carmen Milán-Segovia R; Noyola DE; Nieto-Aguirre K; López-Delarosa A; Romano-Moreno S
    J Clin Pharm Ther; 2008 Jun; 33(3):295-306. PubMed ID: 18452417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy.
    Carlsson KC; Hoem NO; Glauser T; Vinks AA
    Clin Ther; 2005 May; 27(5):618-26. PubMed ID: 15978311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects.
    Mandema JW; Verotta D; Sheiner LB
    J Pharmacokinet Biopharm; 1992 Oct; 20(5):511-28. PubMed ID: 1287200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of ceftazidime and cefepime in burn patients: the importance of age and creatinine clearance.
    Conil JM; Georges B; Lavit M; Seguin T; Tack I; Samii K; Chabanon G; Houin G; Saivin S
    Int J Clin Pharmacol Ther; 2007 Oct; 45(10):529-38. PubMed ID: 17966838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Meta-analysis of the Italian studies on short-term effects of air pollution].
    Biggeri A; Bellini P; Terracini B;
    Epidemiol Prev; 2001; 25(2 Suppl):1-71. PubMed ID: 11515188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The process of knowledge discovery from large pharmacokinetic data sets.
    Ette EI; Williams P; Fadiran E; Ajayi FO; Onyiah LC
    J Clin Pharmacol; 2001 Jan; 41(1):25-34. PubMed ID: 11144991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
    Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
    Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic population study to describe cefepime lung concentrations.
    Breilh D; Saux MC; Delaisement C; Fratta A; Ducint D; Velly JF; Couraud L
    Pulm Pharmacol Ther; 2001; 14(2):69-74. PubMed ID: 11273786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.
    Blair EY; Rivory LP; Clarke SJ; McLachlan AJ
    Br J Clin Pharmacol; 2004 Apr; 57(4):416-26. PubMed ID: 15025739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of cefepime in the neonate.
    Capparelli E; Hochwald C; Rasmussen M; Parham A; Bradley J; Moya F
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2760-6. PubMed ID: 15980347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of ondansetron: a covariate analysis.
    de Alwis DP; Aarons L; Palmer JL
    Br J Clin Pharmacol; 1998 Aug; 46(2):117-25. PubMed ID: 9723819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetic analysis of meropenem in Japanese adult patients.
    Muro T; Sasaki T; Hosaka N; Umeda Y; Takemoto S; Yamamoto H; Kamimura H; Higuchi S; Karube Y
    J Clin Pharm Ther; 2011 Apr; 36(2):230-6. PubMed ID: 21366653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A population pharmacokinetic/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma.
    Johansson ÅM; Hill N; Perisoglou M; Whelan J; Karlsson MO; Standing JF
    Ther Drug Monit; 2011 Dec; 33(6):711-8. PubMed ID: 22105588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.